Salmeterol Xinafoate (Serevent)

A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Also Known As:

Serevent; Salmeterol; Xinafoate, Salmeterol

Networked: 1357 relevant articles (263 outcomes, 497 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Amino Alcohols: 20
    - Ethanolamines: 16
      - Albuterol: 3844
        Salmeterol Xinafoate: 1357
        Fluticasone-Salmeterol Drug Combination: 333
  - Ethylamines: 5
    - Phenethylamines: 28
      - Albuterol: 3844
        Salmeterol Xinafoate: 1357
        Fluticasone-Salmeterol Drug Combination: 333
- Alcohols: 595
  - Amino Alcohols: 20
    - Ethanolamines: 16
      - Albuterol: 3844
        Salmeterol Xinafoate: 1357
        Fluticasone-Salmeterol Drug Combination: 333

Experts

1.	Stempel, David A: 17 articles (12/2016 - 03/2002)
2.	Stanford, Richard H: 16 articles (01/2020 - 02/2004)
3.	Vogelmeier, Claus F: 15 articles (08/2022 - 01/2006)
4.	Jones, Paul W: 14 articles (08/2022 - 02/2007)
5.	Bateman, Eric D: 13 articles (01/2019 - 07/2002)
6.	Banerji, Donald: 13 articles (01/2018 - 03/2013)
7.	Cates, Christopher J: 12 articles (01/2021 - 07/2008)
8.	Fogel, Robert: 12 articles (01/2019 - 01/2015)
9.	Szefler, Stanley J: 12 articles (12/2016 - 04/2005)
10.	Wedzicha, Jadwiga A: 11 articles (01/2021 - 09/2007)

Related Diseases

1.	Asthma (Bronchial Asthma) 06/01/1998 - "Salmeterol xinafoate is a long-acting, highly selective, beta2-adrenergic agonist that produces bronchodilation and clinically significant improvement in pulmonary function for up to 12 hours in patients with asthma. " 02/01/2000 - "Combination treatment with salmeterol 50 microg and FP 250 microg given twice daily from the Diskus device provided better asthma control and greater improvement in pulmonary function than did the individual agents, and may simplify the management of asthma in patients who need both classes of drugs for optimal control of their disease." 07/01/1998 - "Salmeterol is a potent long acting beta-agonist that is effective in relieving the symptoms and airflow limitation of asthma. " 02/01/2000 - "Patients in the combination-product group had a significantly greater probability of remaining in the study without being withdrawn because of worsening asthma than did patients in the placebo, salmeterol, or FP groups (p </= 0.002). " 01/01/2012 - "The asthma was treated successfully with inhaled salmeterol and beclamethasone. "
2.	Chronic Obstructive Pulmonary Disease (COPD) 12/29/2006 - "Several studies have demonstrated that long-acting beta2-agonists such as salmeterol are beneficial in chronic obstructive pulmonary disease (COPD). " 10/01/2002 - "These data indicate that salmeterol is effective and safe in the treatment of acute exacerbation of COPD and support its use in this clinical condition." 03/01/2008 - "The aim of the present study was to evaluate, in patients with COPD, the responsiveness of the ESWT in detecting improvement in walking performance after a single dose of salmeterol. " 06/17/1996 - "This study shows that, compared with placebo, treatment with salmeterol produces an improvement in respiratory symptoms and morning PEF values in patients with moderate to severe COPD. " 07/01/1995 - "This study shows that, compared with placebo, treatment with salmeterol produces an improvement in respiratory symptoms and morning PEF values in patients with moderate to severe COPD. "
3.	Inflammation (Inflammations) 01/01/2006 - "The protection against exacerbations may be attributed to better control of inflammation, AHR and lung function parameters achieved with salmeterol and FP in combination, compared with either treatment alone." 01/01/1992 - "It has been argued that the regular use of salmeterol can mask the worsening of bronchial inflammation although clinical studies have not substantiated this potential risk. " 01/01/2017 - "Salmeterol can significantly inhibit activation of macrophage-mediated inflammation by PgLPS, suggesting that use of salmeterol may be an effective treatment in inhibiting or lessening the inflammatory response mediated through TLR pathway activation." 03/01/2001 - "We studied 13 allergic asthmatics controlled with as needed inhaled short-acting beta(2)-agonists alone, and used bronchoalveolar lavage 5 min and 48 h after SAC to assess airway inflammation, and the effects of salmeterol on this process. " 10/01/2000 - "These findings also indicate, contrary to earlier speculation, that salmeterol does not have a pro-inflammatory effect or mask persistent airway inflammation. "
4.	Dyspnea (Shortness of Breath) 01/01/2000 - "In one study, a dose of salmeterol 50 mcg twice daily produced a reduction in breathlessness and a clinically significant improvement in quality of life. " 12/01/2002 - "Salmeterol reduced the perception of breathlessness (in 6 of 9 studies) and improved health status (in 3 of 4 studies). " 01/01/2002 - "Overall, breathlessness was not reduced, but in one study more subjects in the salmeterol group had low Borg dyspnoea scores compared to placebo (Peto Odds Ratio = 0.60, 95% CI: 0.40; 0.88). " 01/01/2000 - "Breathlessness was reduced in one study in patients receiving salmeterol 50 mcg twice daily group. " 04/01/2005 - "Differences in breathlessness scores were statistically significant after 1 day for the group treated with salmeterol alone and after 2 days for the combination group. "
5.	Exercise-Induced Asthma (Asthma, Exercise Induced) 01/01/1993 - "Salmeterol seems especially effective in patients with nocturnal symptoms, exercise induced asthma, and in patients sensitive to inhaled irritants such as cold air. " 07/16/1998 - "Protection against exercise-induced asthma is maintained with long-term administration of salmeterol, but the length of time that the drug remains active after a single dose decreases." 11/01/1995 - "Thus, inhaled salmeterol 25 and 50 micrograms offered similar overnight protection against exercise-induced asthma and improved baseline lung function in the morning as compared to placebo." 11/01/1995 - "The main aim of the present study was to evaluate whether inhaled salmeterol given in the evening protected against exercise-induced asthma the next morning. " 08/01/1992 - "The effect of inhaled salmeterol xinafoate, a long acting beta 2 agonist, on exercise induced asthma was studied in a double blind, crossover, and placebo controlled trial. "

Related Drugs and Biologics

1.	Fluticasone (Cutivate)
2.	Formoterol Fumarate (Oxis)
3.	Adrenal Cortex Hormones (Corticosteroids)
4.	Tiotropium Bromide (Spiriva)
5.	Albuterol (Salbutamol)
6.	montelukast (Singulair)
7.	Budesonide (Pulmicort)
8.	Bronchodilator Agents (Bronchodilators)
9.	indacaterol
10.	Theophylline (Theon)

Related Therapies and Procedures

1.	Therapeutics
2.	Nebulizers and Vaporizers (Inhaler)
3.	Metered Dose Inhalers (Metered Dose Inhaler)
4.	Respiratory Therapy (Therapy, Respiratory)
5.	Dry Powder Inhalers